CD274 and non-small cell lung carcinoma: In conclusion, metabolic tumor activity as MTV on 18F-FDG uptake could predict the prognosis after first-line pembrolizumab treatment in patients with NSCLC with PD-L1 expression ≥ 50%, especially for patients with Ad.